| Back- |
 | |  | |  | |  | |  | |  | |  | |  |
OzStar Therapeutics Pty Ltd © 2018 Privacy Policy info@ozstartherapeutics.com |
Management
 |
 |
 |
 |
 |
Dr Nick N Gorgani
Inventor, Founder and CEO
Dr Gorgani (BE, MBBS, MS Drug Dev, PhD), is the inventor of this technology and the
founder and CEO of OzStar Therapeutics (April 2010) and GlyConMedics LLC (March
2013). He has gained multidisciplinary training spanning from chemical engineering to
medicine to immunology and to industrial drug development. He has worked for academic
institutions, hospitals and biotechnology/pharmaceutical companies. Nick has led numerous
classes of patentable discoveries including, non-inflammatory disposal of pathogens and
dying cells, the discovery of a new biologic for the treatment of RA and AMD, the discovery
of mechanism of action of a small molecule that mediates immune tolerance, the discovery of
a world first-in-class small molecule for the treatment of proteinuria, and the discovery of a
new therapy for the treatment of type 2 diabetes.
Nick has received numerous awards including Turkish Ministry of Health and Government
scholarships, Australian National University PhD Scholarship, United States Arthritis
Foundation Postdoctoral Fellowship, Scripps Research Institute Society of Fellows
Excellence in Research Award and two grants from the Australian Government. He is a
clinical senior lecturer in the School of Paediatrics and Reproductive Health, University of
Adelaide and at the Department of Medicine, University of Sydney. He has trained a number
of students and postdoctoral fellows and examined a number of PhD and Master’s degree
thesis and peer-reviewed manuscripts for world-leading scientific journals.
Mr. John Fessler
Business Development - San Diego, USA
Mr. Fessler, CPA has over thirty years experience in the Healthcare Industry. John began his
career at Arthur Andersen where he became Partner in Charge of the Strategic Services for
Healthcare in the Western Region. After Andersen John was President of Med Unite which
was grown form concept to over 20M before it was sold to ProxyMed. John has served as a
CEO for start ups HERAE (merged into Med Impact ) and Santech, Inc. Currently , John
consults with 3DT Holdings, a Medical Device Startup, ad is a Entrepreneur in Resident at
Connect - San Diego supporting Life Sciences Companies hone strategy and raise capital.
Mr. Fessler is leading the business development aspects of our company.
Dr Karl HS Kim
Principal Medical Expert - San Diego, USA
Dr Kim (MD, PhD) serves as principal medical expert to our company. Dr. Kim is a physician-
scientist with a unique combination of knowledge, perspectives and experiences across
small biopharma, medium and large pharmaceuticals covering the entire clinical development
aspects including early and late phases (comprising IND, Phases I, II, III, NDA and product
launch activity support) and life-cycle management / post-marketing safety survey, including
Phase IV studies in multiple therapeutic areas at Avanir Pharmaceuticals, Santarus
Pharmaceuticals, Theravance, Bayer HealthCare, and Berlex/Shering AG. Dr. Kim’s diverse
educational backgrounds include B.S. in Electrical Engineering with Biomedical Engineering
Option from Michigan State University, Ph.D. in Neuroscience from Cornell Graduate School
of Medical Sciences / Sloan-Kettering Institute, M.D. from Cornell University Medical College
with Radiology training at Albert Einstein College of Medicine, and Clinical Pharmacology
Research Fellowship at Georgetown University Medical Center.
Dr Kim is leading the clinical safety and trial operations for our phase 2a clinical trial.
Ms Mahnoosh Afkham
Chief Quality Control Officer - San Diego, United States
Ms. Mahnoosh Afkham (BSc, MSc) is a Chief Quality Control Officer of our company. She
has over 20 years of experience in diagnostics and biotechnology with US based companies
such as Gen-Probe and Genentech/Roche. In Australia, Mahnoosh has contributed to
biotechnology and pharmaceutical companies such as Hospira, Adelaide and Sigma
Pharmaceuticals, Sydney and gained experience and expertise in method validation and
analytical method development for quality control of GMP manufactured products.
Mahnoosh has a BSc in Chemistry and an MSc in Analytical Chemistry from San Diego State
University, USA.
Mahnoosh is leading the quality assurance aspects of our products.
Ms Wendy Free
Regulatory Officer - Brisbane, Australia
Ms Free (BSc, M. Tech Management, MASM, MRACI, FAOQ) is regulatory expert, with
specific responsibility for regulatory matters, cGMP manufacture and drug development. Ms
Free has extensive local and international experience in facilitating the successful transition
to the marketplace of a wide range of medicaments and allied technologies. Ms Free
provides consulting advice to a range of organisations including private, public and
government. She is the Managing Director of Quality Matters Safety Matters Pty Ltd,
lectures at University of Queensland, is a mentor for Commercialisation Australia, and an
APVMA GMP auditor.
Ms Free is leading the regulatory aspects of our product development.
Inventor, Founder and CEO
Dr Gorgani (BE, MBBS, MS Drug Dev, PhD), is the inventor of this technology and the
founder and CEO of OzStar Therapeutics (April 2010) and GlyConMedics LLC (March
2013). He has gained multidisciplinary training spanning from chemical engineering to
medicine to immunology and to industrial drug development. He has worked for academic
institutions, hospitals and biotechnology/pharmaceutical companies. Nick has led numerous
classes of patentable discoveries including, non-inflammatory disposal of pathogens and
dying cells, the discovery of a new biologic for the treatment of RA and AMD, the discovery
of mechanism of action of a small molecule that mediates immune tolerance, the discovery of
a world first-in-class small molecule for the treatment of proteinuria, and the discovery of a
new therapy for the treatment of type 2 diabetes.
Nick has received numerous awards including Turkish Ministry of Health and Government
scholarships, Australian National University PhD Scholarship, United States Arthritis
Foundation Postdoctoral Fellowship, Scripps Research Institute Society of Fellows
Excellence in Research Award and two grants from the Australian Government. He is a
clinical senior lecturer in the School of Paediatrics and Reproductive Health, University of
Adelaide and at the Department of Medicine, University of Sydney. He has trained a number
of students and postdoctoral fellows and examined a number of PhD and Master’s degree
thesis and peer-reviewed manuscripts for world-leading scientific journals.
Mr. John Fessler
Business Development - San Diego, USA
Mr. Fessler, CPA has over thirty years experience in the Healthcare Industry. John began his
career at Arthur Andersen where he became Partner in Charge of the Strategic Services for
Healthcare in the Western Region. After Andersen John was President of Med Unite which
was grown form concept to over 20M before it was sold to ProxyMed. John has served as a
CEO for start ups HERAE (merged into Med Impact ) and Santech, Inc. Currently , John
consults with 3DT Holdings, a Medical Device Startup, ad is a Entrepreneur in Resident at
Connect - San Diego supporting Life Sciences Companies hone strategy and raise capital.
Mr. Fessler is leading the business development aspects of our company.
Dr Karl HS Kim
Principal Medical Expert - San Diego, USA
Dr Kim (MD, PhD) serves as principal medical expert to our company. Dr. Kim is a physician-
scientist with a unique combination of knowledge, perspectives and experiences across
small biopharma, medium and large pharmaceuticals covering the entire clinical development
aspects including early and late phases (comprising IND, Phases I, II, III, NDA and product
launch activity support) and life-cycle management / post-marketing safety survey, including
Phase IV studies in multiple therapeutic areas at Avanir Pharmaceuticals, Santarus
Pharmaceuticals, Theravance, Bayer HealthCare, and Berlex/Shering AG. Dr. Kim’s diverse
educational backgrounds include B.S. in Electrical Engineering with Biomedical Engineering
Option from Michigan State University, Ph.D. in Neuroscience from Cornell Graduate School
of Medical Sciences / Sloan-Kettering Institute, M.D. from Cornell University Medical College
with Radiology training at Albert Einstein College of Medicine, and Clinical Pharmacology
Research Fellowship at Georgetown University Medical Center.
Dr Kim is leading the clinical safety and trial operations for our phase 2a clinical trial.
Ms Mahnoosh Afkham
Chief Quality Control Officer - San Diego, United States
Ms. Mahnoosh Afkham (BSc, MSc) is a Chief Quality Control Officer of our company. She
has over 20 years of experience in diagnostics and biotechnology with US based companies
such as Gen-Probe and Genentech/Roche. In Australia, Mahnoosh has contributed to
biotechnology and pharmaceutical companies such as Hospira, Adelaide and Sigma
Pharmaceuticals, Sydney and gained experience and expertise in method validation and
analytical method development for quality control of GMP manufactured products.
Mahnoosh has a BSc in Chemistry and an MSc in Analytical Chemistry from San Diego State
University, USA.
Mahnoosh is leading the quality assurance aspects of our products.
Ms Wendy Free
Regulatory Officer - Brisbane, Australia
Ms Free (BSc, M. Tech Management, MASM, MRACI, FAOQ) is regulatory expert, with
specific responsibility for regulatory matters, cGMP manufacture and drug development. Ms
Free has extensive local and international experience in facilitating the successful transition
to the marketplace of a wide range of medicaments and allied technologies. Ms Free
provides consulting advice to a range of organisations including private, public and
government. She is the Managing Director of Quality Matters Safety Matters Pty Ltd,
lectures at University of Queensland, is a mentor for Commercialisation Australia, and an
APVMA GMP auditor.
Ms Free is leading the regulatory aspects of our product development.
